Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

16 17 18
zadetkov: 175
171.
  • Multicentre analysis of pat... Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?
    Vandesompele, Jo; Speleman, Frank; Van Roy, Nadine ... Medical and pediatric oncology, 01/2001, Letnik: 36, Številka: 1
    Journal Article
    Odprti dostop

    Procedure Analysis of comparative genomic hybridization (CGH) data of 120 tumors from four different studies, and data of 84 previously unpublished tumors, allowed delineation of at least six ...
Celotno besedilo
172.
Celotno besedilo
173.
  • Localized dumbbell neurobla... Localized dumbbell neuroblastoma: a study of 25 cases treated between 1982 and 1987 using the same protocol
    Plantaz, D; Hartmann, O; Kalifa, C ... Medical and pediatric oncology, 1993, Letnik: 21, Številka: 4
    Journal Article

    Among the 108 non-metastatic neuroblastomas treated at the Institut Gustave Roussy between 1982 and 1987, 25 dumbbell neuroblastomas were observed. Therapeutics included: 1) an initial laminectomy in ...
Preverite dostopnost
174.
  • Generation of a humanised s... Generation of a humanised single chain Fv (Scfv) derived from the monoclonal Eric-1 recognising the human neural cell adhesion molecule
    Whittington, Hayley A.; Hancock, Jeremy; Kemshead, John T. Medical and pediatric oncology, 01/2001, Letnik: 36, Številka: 1
    Journal Article

    Background Murine monoclonal antibody (MoAb) ERIC‐1 recognises an epitope on the neural cell adhesion molecule (NCAM) whose expression in paediatric and adult tissues is confined mainly to the brain, ...
Celotno besedilo
175.
  • Long term follow-up after c... Long term follow-up after chilhood cancer
    Plantaz, Dominique; Tabone, Marie-Dominique; Berger, Claire ... La revue du praticien 64, Številka: 9
    Magazine Article

    Five year survival rates among childhood cancer rose to 80%. Relapses are rare after five years of remission. Long term follow-up should also detect treatment related late adverse effects. Repeated ...
Preverite dostopnost

Nalaganje filtrov